Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SOS1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SOS1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SOS1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/SOS1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SOS1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SOS1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SOS1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SOS1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SOS1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SOS1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
GO:00420988 | Cervix | CC | T cell proliferation | 49/2311 | 199/18723 | 1.32e-06 | 4.49e-05 | 49 |
GO:00020111 | Cervix | CC | morphogenesis of an epithelial sheet | 21/2311 | 57/18723 | 1.91e-06 | 5.97e-05 | 21 |
GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
GO:00421297 | Cervix | CC | regulation of T cell proliferation | 43/2311 | 171/18723 | 3.21e-06 | 8.77e-05 | 43 |
GO:00380933 | Cervix | CC | Fc receptor signaling pathway | 19/2311 | 50/18723 | 3.42e-06 | 9.17e-05 | 19 |
GO:19021056 | Cervix | CC | regulation of leukocyte differentiation | 61/2311 | 279/18723 | 5.16e-06 | 1.29e-04 | 61 |
GO:00706637 | Cervix | CC | regulation of leukocyte proliferation | 55/2311 | 245/18723 | 6.51e-06 | 1.56e-04 | 55 |
GO:00506705 | Cervix | CC | regulation of lymphocyte proliferation | 51/2311 | 225/18723 | 1.05e-05 | 2.32e-04 | 51 |
GO:00329444 | Cervix | CC | regulation of mononuclear cell proliferation | 51/2311 | 227/18723 | 1.36e-05 | 2.73e-04 | 51 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa040722 | Oral cavity | EOLP | Phospholipase D signaling pathway | 31/1218 | 148/8465 | 1.82e-02 | 4.67e-02 | 2.76e-02 | 31 |
hsa0516355 | Oral cavity | EOLP | Human cytomegalovirus infection | 68/1218 | 225/8465 | 5.29e-10 | 1.90e-08 | 1.12e-08 | 68 |
hsa0516051 | Oral cavity | EOLP | Hepatitis C | 52/1218 | 157/8465 | 1.79e-09 | 4.81e-08 | 2.84e-08 | 52 |
hsa0520855 | Oral cavity | EOLP | Chemical carcinogenesis - reactive oxygen species | 66/1218 | 223/8465 | 2.50e-09 | 5.76e-08 | 3.40e-08 | 66 |
hsa0451036 | Oral cavity | EOLP | Focal adhesion | 60/1218 | 203/8465 | 1.42e-08 | 1.83e-07 | 1.08e-07 | 60 |
hsa051615 | Oral cavity | EOLP | Hepatitis B | 49/1218 | 162/8465 | 1.38e-07 | 1.54e-06 | 9.07e-07 | 49 |
hsa0466031 | Oral cavity | EOLP | T cell receptor signaling pathway | 34/1218 | 104/8465 | 1.63e-06 | 1.39e-05 | 8.18e-06 | 34 |
hsa0516551 | Oral cavity | EOLP | Human papillomavirus infection | 79/1218 | 331/8465 | 1.96e-06 | 1.63e-05 | 9.60e-06 | 79 |
hsa046623 | Oral cavity | EOLP | B cell receptor signaling pathway | 29/1218 | 84/8465 | 2.75e-06 | 2.11e-05 | 1.25e-05 | 29 |
hsa0521052 | Oral cavity | EOLP | Colorectal cancer | 29/1218 | 86/8465 | 4.71e-06 | 3.17e-05 | 1.87e-05 | 29 |
hsa0521151 | Oral cavity | EOLP | Renal cell carcinoma | 25/1218 | 69/8465 | 4.96e-06 | 3.27e-05 | 1.93e-05 | 25 |
hsa0472252 | Oral cavity | EOLP | Neurotrophin signaling pathway | 36/1218 | 119/8465 | 6.23e-06 | 3.87e-05 | 2.28e-05 | 36 |
hsa0521534 | Oral cavity | EOLP | Prostate cancer | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa0520553 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa046501 | Oral cavity | EOLP | Natural killer cell mediated cytotoxicity | 38/1218 | 132/8465 | 1.26e-05 | 7.01e-05 | 4.13e-05 | 38 |
hsa0401233 | Oral cavity | EOLP | ErbB signaling pathway | 27/1218 | 85/8465 | 3.39e-05 | 1.69e-04 | 9.94e-05 | 27 |
hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa0466411 | Oral cavity | EOLP | Fc epsilon RI signaling pathway | 23/1218 | 68/8465 | 4.23e-05 | 2.01e-04 | 1.19e-04 | 23 |
hsa0152134 | Oral cavity | EOLP | EGFR tyrosine kinase inhibitor resistance | 25/1218 | 79/8465 | 7.03e-05 | 3.25e-04 | 1.91e-04 | 25 |
hsa0401033 | Oral cavity | EOLP | MAPK signaling pathway | 68/1218 | 302/8465 | 7.48e-05 | 3.40e-04 | 2.01e-04 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SOS1 | SNV | Missense_Mutation | | c.598A>G | p.Thr200Ala | p.T200A | Q07889 | protein_coding | tolerated(0.09) | benign(0) | TCGA-A2-A0SX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
SOS1 | SNV | Missense_Mutation | novel | c.1468C>A | p.Leu490Ile | p.L490I | Q07889 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SOS1 | SNV | Missense_Mutation | rs727505383 | c.3433G>A | p.Asp1145Asn | p.D1145N | Q07889 | protein_coding | deleterious(0.03) | benign(0.053) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SOS1 | SNV | Missense_Mutation | | c.1846N>T | p.His616Tyr | p.H616Y | Q07889 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
SOS1 | insertion | Nonsense_Mutation | novel | c.517_518insACTGTAGCCACACAGCCATAAATGACTGATAAGAGAAACAGTG | p.Met173AsnfsTer10 | p.M173Nfs*10 | Q07889 | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
SOS1 | insertion | Frame_Shift_Ins | novel | c.3688_3689insAAAAGAT | p.Pro1230GlnfsTer16 | p.P1230Qfs*16 | Q07889 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
SOS1 | deletion | Frame_Shift_Del | novel | c.2848delN | p.Arg950AspfsTer7 | p.R950Dfs*7 | Q07889 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
SOS1 | SNV | Missense_Mutation | novel | c.451A>C | p.Asn151His | p.N151H | Q07889 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SOS1 | SNV | Missense_Mutation | rs371408734 | c.3709N>G | p.Pro1237Ala | p.P1237A | Q07889 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.986) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
SOS1 | SNV | Missense_Mutation | novel | c.3150N>A | p.Met1050Ile | p.M1050I | Q07889 | protein_coding | tolerated(0.18) | benign(0.048) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |